Vertex Pharmaceuticals (VRTX) Gains from Sales and Divestitures (2010 - 2011)
Vertex Pharmaceuticals (VRTX) recorded quarterly Gains from Sales and Divestitures of $747000.0 in Q4 2011, up 37.32% quarter-over-quarter from $544000.0 in Q4 2010, and up 37.32% on a YoY basis from $544000.0 in Q4 2010.
Vertex Pharmaceuticals (VRTX) Gains from Sales and Divestitures (2010 - 2011) Analysis & Trends
Vertex Pharmaceuticals' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $747000.0 for Q4 2011.
- In Q4 2011, Gains from Sales and Divestitures rose 37.32% year-over-year to $747000.0; the TTM figure through Dec 2011 stood at $747000.0 (up 37.32% YoY), while the FY2011 annual figure was $747000.0, up 37.32% from the prior year.
- Gains from Sales and Divestitures was $747000.0 for Q4 2011 at Vertex Pharmaceuticals, up from $544000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $747000.0 in Q4 2011 to a low of $544000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 747,000.00 |
| Dec 31, 2011 | 747,000.00 |
| Dec 31, 2010 | 544,000.00 |
| Dec 31, 2010 | 544,000.00 |